High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane

High ctDNA molecule numbers relate with poor outcome in advanced ER+, HER2− postmenopausal breast cancer patients treated with everolimus and exemestane

We determined whether progression‐free survival (PFS) in metastatic breast cancer (MBC) patients receiving everolimus plus exemestane (EVE/EXE) varies depending on circulating tumour DNA (ctDNA) characteristics. Baseline plasma cell‐free DNA (cfDNA) from 164 postmenopausal women with ER‐positive, HE...

Full description

Bibliographic Details
Main Authors: Dinja T. Kruger, Maurice P.H.M. Jansen, Inge R.H.M. Konings, Wouter M. Dercksen, Agnes Jager, Jamal Oulad Hadj, Stefan Sleijfer, John W.M. Martens, Epie Boven
Format: Article
Language:English
Published: Wiley 2020-03-01
Series:Molecular Oncology
Subjects:
biomarker
ctDNA
everolimus
metastatic breast cancer
Online Access:https://doi.org/10.1002/1878-0261.12617

Internet

https://doi.org/10.1002/1878-0261.12617

Similar Items